Skip to main content
Clinical Trials/NCT02228291
NCT02228291
Completed
Not Applicable

The Effect of Citric Flavonoid Administration on Endothelial Function and Gut Barrier Function

Maastricht University Medical Center1 site in 1 country68 target enrollmentMarch 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obesity
Sponsor
Maastricht University Medical Center
Enrollment
68
Locations
1
Primary Endpoint
Endothelial function
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

This randomized, double-blind, placebo-controlled, parallel study aims to determine the 6-week and acute effects of daily administration of a citrus flavonoid on cardiovascular and intestinal health as assessed by investigation of endothelial function, blood pressure and heart rate, glucose/insulin metabolism, lipid profile and gut barrier function in overweigh subjects.

Futhermore we aim to relate the specific intestinal (microbial) metabolism with final serum levels of specific metabolites of the study product.

Registry
clinicaltrials.gov
Start Date
March 2014
End Date
December 2014
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Bouke Salden

Coordinating Investigator

Maastricht University Medical Center

Eligibility Criteria

Inclusion Criteria

  • Overweight men/women (BMI 25-35 kg/m2)
  • Healthy individuals
  • Age between 18 and 70 years
  • Fasting glucose \< 7.0 mmol/L
  • Normal HbA1c (4.4 to 6.2%)

Exclusion Criteria

  • Type 2 diabetes mellitus (defined as fasting plasma glucose ≥ 7.0 mmol/L)
  • Gastroenterological diseases or abdominal surgery
  • Cardiovascular diseases, cancer, liver or kidney malfunction, thyroid disorders, disease with a life expectancy shorter than 5 years
  • Self-admitted HIV-positive status
  • Abuse of products; alcohol (\> 20 alcoholic consumptions per week) and drugs
  • Plans to lose weight or following a hypocaloric diet during the study period
  • Weight gain or loss \> 3 kg in previous 3 months
  • Use of medication interfering with endpoints
  • Intake of antihypertensive medication, statins, corticosteroids, NSAIDs, ciclosporin A, rifampicin are strictly forbidden
  • Use of antioxidants, minerals and vitamin supplements available in pharmacies, drugstores, food markets or in alternative medicine

Outcomes

Primary Outcomes

Endothelial function

Time Frame: 6 weeks

The primary objective of this study is to evaluate the efficacy on endothelial function, as assessed by flow mediated dilatation (FMD) measurements, after 6 weeks of administration of study product.

Secondary Outcomes

  • Glucose / insulin metabolism(6 weeks)
  • Endothelial function(6 weeks)
  • Blood pressure & heart rate(6 weeks)
  • Gut barrier function(6 weeks)
  • Colonic inflammation(6 weeks)
  • Bioavailability and metabolism(5 days)
  • Lipid profile(6 weeks)

Study Sites (1)

Loading locations...

Similar Trials